Presently, Garry E. Menzel is President, Chief Executive Officer & Director at TCR2 Therapeutics, Inc.

He is also on the board of Epilepsy Therapy Project, Stoke Therapeutics, Inc. and Black Diamond Therapeutics, Inc. and Member-National Board at Epilepsy Foundation and Principal at Royal College of Art.

Garry E. Menzel previously was Chief Operating Officer of Regulus Therapeutics, Inc., Chief Financial Officer for DaVita, Inc., Managing Director at Credit Suisse Group AG, Managing Director at The Goldman Sachs Group, Inc., Consultant at Bain & Co., Inc., Chief Strategy Officer for Axcella Health, Inc. and Research Assistant at Smithkline Beecham Plc.

Garry E. Menzel received an undergraduate degree from Imperial College London, an MBA from Stanford Graduate School of Business and a doctorate from the University of Cambridge.